HOME >> MEDICINE >> NEWS
Caring for the sick now a public health priority for developing countries

Of the 57 million people dying worldwide each year, 6 million deaths are caused by cancer and 3 million from HIV/AIDS, with the majority of both occurring in developing countries. These figures indicate the large number of people experiencing incapacitation and pain through shortness of breath, constipation, diarrhoea, nausea as well as distress, depression and anxiety.

New research published in the Journal of Public Health Policy, prepared by research staff at The George Institute for International Health, the School of Public Health at the University of Sydney and the Department of Palliative Medicine at Calvary Hospital, highlights that a potential 100 million people in these poorer nations could benefit from palliative care services, including family members and close companions.

Lead author of the paper Dr Ruth Webster, a Research Fellow at The George Institute, says that "The scale of this epidemic of death and dying requires acknowledgement and priority as a public health issue, with more than just an emphasis on prevention of these diseases and their cure. Around 100 countries around the world have palliative care services, however only 6% are located in Asia and Africa, where the highest demand for the services is".

"Palliative care is not on the health agenda of governments as a public health problem, which is extremely detrimental to the populations that most need these services. WHO has recommended that all countries have a policy to implement these types of services, but despite this, one only African country, has made this a priority, Uganda. South Africa has recently included palliative care in their new health policies." added Dr Webster.

The review found three specific barriers to implementing palliative care in developing countries - government commitment, opioid availability and education. While pain management is only part of the picture, the availability of opioids and morphine is extremely diffi
'"/>

Contact: Emma Orpilla
eorpilla@george.org.au
61-299-934-592
Research Australia
9-May-2007


Page: 1 2

Related medicine news :

1. Caring for cancer carers: Are womens needs different from mens?
2. National Academies Advisory -- June 8 public briefing on LANL groundwater protection
3. The general public lacks basic medical knowledge
4. Free public talk on epilepsy research and progress towards better treatment
5. Post-traumatic stress disorder 10 times higher in New Orleans than in the general public
6. Hurricane Katrina evacuees had deep distrust of public health authorities
7. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
8. RAND panel identifies key components of public health emergency preparedness
9. March 30 public briefing on PEPFARs Progress
10. Biosand filter reduces diarrheal disease in Dominican Republic villages
11. Mercury contamination of fish warrants worldwide public warning

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: